

# Leukotriene B<sub>4</sub> pathway regulates the fate of the hematopoietic stem cells

Jin Woong Chung<sup>1</sup>, Geun-Young Kim<sup>1</sup>,  
Yeung-Chul Mun<sup>2</sup>, Ji-Young Ahn<sup>2</sup>,  
Chu-Myong Seong<sup>2</sup> and Jae-Hong Kim<sup>1,3</sup>

<sup>1</sup>School of Life Sciences and Biotechnology  
Korea University, Seoul 136-701, Korea

<sup>2</sup>Department of Oncology/Hematology  
College of Medicine, Ewha Woman's University  
Seoul 158-056, Korea

<sup>3</sup>Corresponding author: Tel, 82-2-3290-3452;  
Fax, 82-2-3290-3960; E-mail, jhongkim@korea.ac.kr

Accepted 31 January 2005

Abbreviations: FL, Flt-3 ligand; HSC, hematopoietic stem cell; LTB<sub>4</sub>, leukotriene B<sub>4</sub>; RT-PCR, reverse transcription PCR; TPO, thrombopoietin; UCB, umbilical cord blood

## Abstract

Leukotriene B<sub>4</sub> (LTB<sub>4</sub>), derived from arachidonic acid, is a potent chemotactic agent and activating factor for hematopoietic cells. In addition to host defense *in vivo*, several eicosanoids have been reported to be involved in stem cell differentiation or proliferation. In this study, we investigated the effect of LTB<sub>4</sub> on human cord blood CD34<sup>+</sup> hematopoietic stem cells (HSCs). LTB<sub>4</sub> was shown to induce proliferation of HSC and exert anti-apoptotic effect on the stem cells. Blockade of interaction between LTB<sub>4</sub> and its receptor enhanced self-renewal of the stem cells. Effect of LTB<sub>4</sub> on differentiation of CD34<sup>+</sup> HSCs were confirmed by clonogenic assays, and induction of the expression of BLT2 (the low-affinity LTB<sub>4</sub> receptor), during the *ex vivo* expansion was confirmed by reverse transcription-PCR. Our results suggest that LTB<sub>4</sub>-BLT2 interaction is involved in the cytokine-induced differentiation and *ex vivo* expansion of hematopoietic stem cells.

**Keywords:** BLT<sub>2</sub>; CD34; apoptosis; cell differentiation; hematopoietic stem cells; leukotriene B<sub>4</sub>; receptors

## Introduction

Hematopoietic stem cells (HSCs) have ability to self renew while functionally repopulating the cells of the blood and lymph for the life of an individual. These cells are thought to retain a high capacity for plasticity that would contribute to their ability to differentiate into not only hematopoietic cells but also non-hematopoietic tissues such as brain, heart, skeletal muscle, liver and endothelial cells, following injury or stress (Heike *et al.*, 2004). Such capacity of these cells gives rise to the hope that hematopoietic stem cells may regenerate various damaged tissues. In that regard, *ex vivo* expansion of hematopoietic stem cells is a promising technology for many potential applications from marrow reconstitution to gene therapy. Despite of considerable progresses gained during the past ten years in understanding the biology of hematopoietic stem cells and its *ex vivo* expansion, the success was limited (Piacibello *et al.*, 1997; Shih *et al.*, 1999; Lewis *et al.*, 2001). Self-renewal of stem cells depends on several critical factors, including the hematopoietic microenvironment, interactions with supporting stromal cells (Charbord, 2001), features of the extracellular matrix (Williams *et al.*, 1991), hematopoietic growth factors (Feugier *et al.*, 2002; Terada *et al.*, 2003) and cytokines (Flores-Guzman *et al.*, 2002).

Leukotriene B<sub>4</sub> (LTB<sub>4</sub>), derived from arachidonic acid, is a potent chemotactic agent and activating factor for hematopoietic cells. Until recently, two cell surface receptors for LTB<sub>4</sub> have been identified; BLT1, a high affinity receptor, and BLT2, a low-affinity receptor. BLT2 is expressed ubiquitously, in contrast to BLT1 expressed predominantly in leukocytes. The differences in the distribution and pharmacological characteristics of BLT1 and BLT2 suggest distinct role(s) for these receptors *in vivo* (Toda *et al.*, 2002). Based on the previous observations, LTB<sub>4</sub> seems to play important roles in inflammation in addition to host defense *in vivo* (S.W. Crooks *et al.*, 1998). Recently, it has been reported that cysteinyl leukotriene receptor is involved in differentiation of HSCs into eosinophils (Hashida *et al.*, 2001). In addition, several eicosanoids have been reported to be involved in stem cell differentiation or proliferation (Desplat *et al.*, 2000; Braccioni *et al.*, 2002). In this study, we have investigated the effect of LTB<sub>4</sub>, one of the potent lipid mediators, on cell proliferation, differentiation, and self-renewal capacity during the long-term culture of HSCs.

## Materials and Methods

### Cell source and CD34<sup>+</sup> cell purification

Umbilical cord blood was obtained at the end of full-term deliveries. Mononuclear cells were isolated using a Ficoll-Hypaque (density, 1.077; Pharmacia Biotech, Upsala, Sweden) density gradient centrifugation. After two cycles of plastic adherence for 60 min, the cells were washed and suspended in PBS (phosphate buffered saline) (pH 7.4), which contained 0.1% bovine serum albumin. During these procedures, all adherent cells were removed and only nonadherent cells were recovered. The CD34<sup>+</sup> cell fraction was isolated with a superparamagnetic microbead selection using monoclonal antibody (QBEND10) and miniMACS columns (Miltenyi Biotec; Bergisch Gladbach, Germany) (Kim, 2003). The efficiency of purification and immunophenotype were verified with flow cytometry and counterstained with a FITC-anti-human CD34 (HPCA-2; Becton Dickinson; Mountain View, California) as previously described (Yoo *et al.*, 1999).

### Ex vivo expansion of CD34<sup>+</sup> hematopoietic stem cells

CD34<sup>+</sup> cells were placed into 24-well plates (Falcon; Becton Dickinson Biosciences) at a concentration of  $1 \times 10^3$  cells per well. Each well contained 0.5 ml liquid medium plus the growth factors of interest. The culture medium consisted of Iscove's modified Dulbecco's medium (IMDM; Gibco BRL) supplemented with 10% fetal bovine serum. The cytokines included recombinant human G-CSF (100 U/ml), TPO (10 U/ml), and FL (50 ng/ml). The cultures were incubated at 37°C in a humidified atmosphere containing 5% CO<sub>2</sub>. On day 14, cells were harvested from the culture and the number of viable cells was determined by trypan blue exclusion. Cell counts were also performed using a hemocytometer. The cells from these aliquots were assayed for the number of hematopoietic progenitor cells. Apoptosis assay was performed using Annexin-V-Fluorescein staining kit (Roche) following the manufacturer's protocol.

### Clonogenic assays

Clonogenic assays were performed as follows:  $1 \times 10^3$  CD34<sup>+</sup> UCB cells were cultured at two plates per point in complete methylcellulose medium (HCC-4434; Methocult; Stem Cell Technologies, Vancouver, Canada). It was supplemented with 50 ng/ml stem cell factor (SCF), 10 ng/ml interleukin-3, GM-CSF, and 1 U/ml recombinant human erythropoietin (EPO) at 37°C in a humidified atmosphere at 5% CO<sub>2</sub>. After 14 days of incubation, colonies were enumerated with the aid of an inverted microscope and counted by morphologic criteria.

### Reverse transcription (RT)-PCR

Total cellular RNA was extracted from HSCs and dissolved in DEPC (diethylpyrocarbonate)-treated water. One microgram of the extracted RNA was reverse transcribed into cDNA and amplified to determine both BLT2 and GAPDH mRNA expression according to manufacturer's protocol (Reverse-iT™ One-Step RT-PCR Kit; ABgene). Primers for human BLT2 are 5'-AGCCTGGAGACTCTGACCGCTTTCG-3' (forward) and 5'-GACGTAGAGCACCGGTTGACGCTA-3' (reverse) (Tong *et al.*, 2002). Primers for GAPDH are 5'-CTGCACCACCAACTGCTTAGC-3' (forward) and 5'-CTTCACCACCTTCTTGATGTC-3' (reverse). The mixture for BLT2 was heated at 94°C for 20 s, annealed at 68°C for 30 s and extended at 72°C for 30 s for 30 repetitive cycles. The mixture for GAPDH was heated at 94°C for 20 s, annealed at 58°C for 30 s and extended at 72°C for 30 s for 25 repetitive cycles. GAPDH was used as an internal control. The final PCR products were separated on a 1.2% agarose gel with ethidium bromide and visualized under UV light.


### Data analysis and statistics

The results are presented as the mean  $\pm$  SD of the data obtained from three or more experiments performed in duplicates. Statistical comparisons between groups were made with the Student's *t*-test. Values of  $P < 0.05$  were considered significant.

## Results

### LTB<sub>4</sub> induces proliferation of CD34<sup>+</sup> HSCs

The effect of LTB<sub>4</sub> on the *in vitro* proliferation of CD34<sup>+</sup> hematopoietic progenitor cells from freshly purified UCB CD34<sup>+</sup> cells was assessed using trypan blue exclusion assay. Earlier report of optimal culture condition for hematopoietic stem cells with combined supplementation of G-CSF, TPO and FL (Yoo *et al.*, 1999) was used as a control culture and compared with the additional supplementation of LTB<sub>4</sub>. In the absence of exogenous cytokines, no viable cells were observed after 2 weeks of culture, regardless of whether or not LTB<sub>4</sub> was present (data not shown). When mixture of G-CSF, TPO, and FL was added to the medium, the number of total cells was increased approximately 350 folds during the culture as expected (data not shown). Addition of LTB<sub>4</sub> (300 nM) significantly enhanced the growth of CD34<sup>+</sup> HSCs approximately by 1.5 fold when compared to the condition where no LTB<sub>4</sub> was added (Figure 1A). The effect of LTB<sub>4</sub> was abolished by the addition of CP105696 (10  $\mu$ M), an antagonist of LTB<sub>4</sub> receptors (BLT) (Figure 1A), suggesting the specific effect of LTB<sub>4</sub> on the proliferation of CD34<sup>+</sup> hematopoietic stem cells.



**Figure 1.** Effects of LTB<sub>4</sub> on differentiation of CD34<sup>+</sup> hematopoietic stem cells. (A) Total number of mononuclear cells in liquid culture. Freshly isolated CD34<sup>+</sup> cells were cultured in 10% IMDM with G-CSF (10 U/ml, G), TPO (T) and FL (F) in the absence or the presence of LTB<sub>4</sub> (300 nM) and/or CP105696 (10 μM). On day 14, cells were harvested from each culture and the viable cells were counted using trypan blue. Values are the means ± SD of 3 separate experiments in duplicate cultures (\**P* < 0.05). (B) Purity of CD34<sup>+</sup> HSCs after long term culture. The cells obtained after 2-week culture were stained with FITC-anti-CD34 (HPCA-2) antibody, and analyzed by flow cytometry. Data are presented as means of fluorescence (\**P* < 0.05). (C) Effects of LTB<sub>4</sub> on *in vitro* clonal growth of hematopoietic progenitor cells from isolated human UCB CD34<sup>+</sup> cells. Freshly isolated CD34<sup>+</sup> cells (1 × 10<sup>3</sup> cells/ml) were incubated in a liquid culture as described in the legend of (A). On day 14, cells harvested from each culture were plated into a methylcellulose culture supplemented with SCF, IL-3, GM-CSF, G-CSF and EPO. The culture was incubated for 14 days. Values are the means ± SD of three separate experiments in duplicated cultures.


#### LTB<sub>4</sub> exerts anti-apoptotic effect on CD34<sup>+</sup> hematopoietic stem cells

LTB<sub>4</sub> was reported to be involved in cell survival by its anti-apoptotic effect on various cells such as neutrophil (Hebert *et al.*, 1996; Zhang *et al.*, 2002). We performed Annexin-V staining to determine whether LTB<sub>4</sub> exerts anti-apoptotic effect also on CD34<sup>+</sup> HSCs in a long term culture. As seen in Figure 2, addition of LTB<sub>4</sub> decreased apoptosis when compared to the control and CP105696 treatment inhibited the anti-apoptotic effect of LTB<sub>4</sub> statistically significantly (*P* < 0.05). These results suggest that the growth advantage of LTB<sub>4</sub> on HSC is, at least partly, due to its anti-apoptotic effect.

#### LTB<sub>4</sub> induces differentiation of CD34<sup>+</sup> HSCs

After 2 weeks of *ex vivo* expansion, purity of CD34<sup>+</sup> HSCs was assessed by flow cytometry using CD34 antibody. Interestingly, the results were opposite to the growth experiments, where treatment of LTB<sub>4</sub> showed lowest purity of HSCs in terms of retention of CD34 (Figure 1B). Accordingly, addition of BLT antagonist showed highest CD34-positive populations

(Figure 1B). The fact that the specific antagonist increased the purity of CD34<sup>+</sup> HSCs even in the absence of LTB<sub>4</sub> might be due to the blockade of interaction between BLT and the endogenously produced LTB<sub>4</sub> during differentiation of CD34<sup>+</sup> HSCs (Spanbroek *et al.*, 2000). These results suggest that LTB<sub>4</sub> induces differentiation of HSCs through its receptor during *ex vivo* expansion by autocrine or paracrine manner, since the cells that lost CD34 might be differentiated or at least differentiating cells. Thus, we next performed clonogenic assays with methylcellulose cultures to confirm the involvement of LTB<sub>4</sub> in HSC differentiation. In the methylcellulose cultures, addition of LTB<sub>4</sub> yielded approximately two-fold increase in colony formations of CFU-GM and CFU-GEMM, when compared to the condition where no LTB<sub>4</sub> was added (Figure 1C). Again, this effect was inhibited by the addition of BLT antagonist, CP105696 (10 nM). In contrast, no significant differences in BFU-E-derived colony formation were observed in the presence or the absence of LTB<sub>4</sub> or CP105696 (Figure 1C). Taken together, these results suggest that LTB<sub>4</sub> may induce differentiation of CD34<sup>+</sup> HSCs by its receptor-mediated interaction.




**Figure 2.** Anti-apoptotic effect of LTB<sub>4</sub> on human cord blood CD34<sup>+</sup> cells. Human cord blood stem cells were isolated and cultured in the same condition described in the legend of Figure 1 (A). After two-week culture, cells were harvested and subjected to Annexin V-staining and rate of apoptosis was calculated following the manufacturer's protocol. Values are the means ± SD of 3 separate experiments in duplicate cultures (\**P* < 0.05).

**Blockade of LTB<sub>4</sub> pathway induces self-renewal of CD34<sup>+</sup> HSCs**


From the above results, we assumed that it might be possible that self-renewal of CD34<sup>+</sup> HSC can be increased by blocking LTB<sub>4</sub>-BLT interaction. Thus, we next determined the effect of BLT antagonist on self-renewal of CD34<sup>+</sup> HSCs. After two weeks of *ex vivo* expansion, the cultures were collected and run through the MACS column as mentioned above. After purification of CD34<sup>+</sup> cells, number of the cells was assessed by trypan blue exclusion. As expected, treatment of CD105696 (10 μM) increased number of CD34<sup>+</sup> HSCs by approximately two-fold, compared to the control, whether LTB<sub>4</sub> was added or not (Figure 3A). Even though there might be loss of a small portion of the cells during the purification, this result showed the similar tendency with absolute number of CD34<sup>+</sup> cells (Figure 3B) calculated from total number of the cells (Figure 1A) and the purity of CD34<sup>+</sup> HSCs (Figure 1B), confirming blockade of BLT induces proliferation of CD34<sup>+</sup> HSCs. Since these CD34<sup>+</sup> cells retained differentiating capacity as measured in clonogenic assays using methyl cellulose medium (data not shown), blockade of BLT may induce not only the proliferation but also the self-renewal of CD34<sup>+</sup> HSCs.

**Expression of BLT2, a receptor for LTB<sub>4</sub>, is induced during differentiation of CD34<sup>+</sup> HSCs**

The induced expression of BLT1 during the cytokine-induced differentiation of CD34<sup>+</sup> stem cells was reported by Pettersson *et al.* (2003). We next performed RT-PCR with BLT2-specific primers to investigate whether expression of BLT2, another receptor for LTB<sub>4</sub> is also related to *in vitro* differentiation of CD34<sup>+</sup> HSCs. As seen in Figure 4, BLT2 expression was increased during the long term culture when the



**Figure 3.** Effects of BLT-antagonist on self-renewal of human UCB CD34<sup>+</sup> cells. A. Freshly isolated CD34<sup>+</sup> cells (1×10<sup>3</sup> cells/ml) were *ex vivo* expanded in a liquid culture as described in the legend of Figure 1 (A). On day 14, total cells in each well were harvested and subjected to MACS purification. Numbers of CD34<sup>+</sup> cells in each well were determined under microscope, and the values were expressed as the means ± SD (\**P* < 0.05). B. Absolute number of CD34<sup>+</sup> HSCs calculated from Figure 1A and 1B.



**Figure 4.** Expression of BLT2 in CD34<sup>+</sup> HSCs during long term culture. Total RNAs were isolated from *ex vivo* expanded HSCs and subjected to RT-PCR as described in the Material and Methods.

cytokines were added in the presence or absence of LTB<sub>4</sub>. However, the expression was decreased when the LTB<sub>4</sub> receptor antagonist was treated. Taken together with previous report, these results show the expression of BLT maybe directly or at least indirectly

related to the effect of LTB<sub>4</sub> on HSCs' proliferation, survival, differentiation and self-renewal.

## Discussion

Maintaining self-renewal and differentiation potential of hematopoietic stem cell (HSC) is a crucial component and a major challenge in stem cell research and potential clinical applications for HSC *ex vivo* expansion including tumor cell purging, gene therapy, and stem cell transplantation. In the present study, effects of LTB<sub>4</sub> and its receptor on *ex vivo* expansion, differentiation and self-renewal of hematopoietic stem cells were determined.

LTB<sub>4</sub> has been reported to enhance growth of a variety of cells including human pancreatic cancer cells (Tong *et al.*, 2002), and fibroblast (Woo *et al.*, 2002). In addition, various cytokines, evaluated for their ability to support human HSC long-term *ex vivo* expansion, share many common characteristics with LTB<sub>4</sub>, such as proinflammatory effects, chemotactic activities and growth-stimulating factors, and suggests that LTB<sub>4</sub> might also be involved in the proliferation phase of HSCs.

In our study, LTB<sub>4</sub> itself was unable to induce proliferation of HSC in the absence of other cytokines or even in the presence of any one or two combinations of three cytokines used in this study (data not shown). This is consistent with previous report where LTB<sub>4</sub> had no effect on proliferation of CD34<sup>+</sup> HSCs in the absence of any cytokines (Desplat *et al.*, 2000). However, when LTB<sub>4</sub> was added to the culture medium supplemented with all three cytokines including G-CSF, TPO and FL, the growth of HSCs was increased by approximately 50%, compared to the control. Thus, mechanism of LTB<sub>4</sub> in HSC proliferation is not solely due to self-mediated action but due to the concerted actions of other cytokines. For example, the cytokines might activate LTB<sub>4</sub> signaling pathway or induce the expression of the proteins involved in LTB<sub>4</sub> signaling. Certain cytokines such as IL-13 up-regulates leukotriene receptor in human lung fibroblast (Chibana *et al.*, 2003). Indeed, the expression of BLT2, a LTB<sub>4</sub> receptor, was induced during *ex vivo* expansion of HSCs in the presence of the cytokines (Figure 4), suggesting the cytokines might up-regulate the expression of BLT2, directly or indirectly. Interestingly, the treatment of BLT2 antagonist induced down-regulation of the BLT2 itself expression implicating autocrine regulation of the receptor expression.

Several eicosanoids, including prostaglandins and leukotrienes, have been reported to regulate cellular differentiation and apoptosis (Rudolph *et al.*, 2001). Our results also showed anti-apoptotic effect of LTB<sub>4</sub> on HSCs, suggesting the increase of the number of HSCs in the long term culture by LTB<sub>4</sub> is, at least in part, due to the retardation of apoptosis. Even though the total cell number was increased, population of CD34 positive cells in LTB<sub>4</sub>-treated cells was lower than that of control. However, when the LTB<sub>4</sub> receptor antagonist was treated, retention rate of

CD34 was even higher than that of control, suggesting LTB<sub>4</sub> induces differentiation of HSCs during *ex vivo* expansion. This was confirmed by the clonogenic assay, where LTB<sub>4</sub> treatment enhanced differentiation of HSC into various hematopoietic progenitors including CFU-GM and CFU-GEMM. The fact that absolute number of CD34-positive cells was higher when the HSCs were treated with BLT antagonist, even though the total cell number was relatively lower, suggests that the regulation of LTB<sub>4</sub> signaling pathway may contribute to the self-renewal as well as differentiation of HSCs. Taken together, LTB<sub>4</sub>-BLT interaction is closely related to the cytokines-induced hematopoietic stem cell proliferation, differentiation, and self-renewal, and it might be possible to determine the stem cell fate as needed, i.e. towards self-renewal or differentiation, during *ex vivo* expansion by controlling LTB<sub>4</sub>-BLT2 signaling pathway.

Stem cells can be used to treat a variety of diseases and several recent studies in animal models demonstrate the potential of bioengineering strategies targeting adult and embryonic stem cells. In order to obtain the desired cells for transplantation, stem cell bioengineering approaches involve the manipulation of environmental signals influencing cell survival, proliferation, self-renewal and differentiation. In that regard, even though the exact mechanisms are still to be elucidated, our findings will facilitate the studies and the clinical applications in the field of the stem cell-based regenerative therapies, as treatment accessibility will depend on the development of powerful technologies to produce sufficient cell numbers.

## Acknowledgement

This work was supported by grants from Korea Research Foundation (KRF-2003-003-C00110).

## References

- Braccioni F, Dorman SC, O'byrne PM, Inman MD, Denburg JA, Parameswaran K, Baatjes AJ, Foley R, Gauvreau GM. The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects. *J Allergy Clin Immunol* 2002;110:96-101
- Charbord P. The hematopoietic stem cell and the stromal microenvironment. *Therapie* 2001;56:383-4
- Chibana K, Ishii Y, Asakura T, Fukuda T. Up-regulation of cysteinyl leukotriene 1 receptor by IL-13 enables human lung fibroblasts to respond to leukotriene C4 and produce eotaxin. *J Immunol* 2003;170:4290-5
- Crooks SW, Stockley RA. Leukotriene B<sub>4</sub>. *Int J Biochem Cell Biol* 1998;30:173-8
- Desplat V, Ivanovic Z, Dupuis F, Faucher JL, Denizot Y, Praloran V. Effects of lipoxygenase metabolites of arachidonic acid on the growth of human blood CD34<sup>+</sup> progenitors. *Blood Cells Mol Dis* 2000;26:427-36
- Feugier P, Jo DY, Shieh JH, MacKenzie KL, Rafii S, Crystal

RG, Moore MA. *Ex vivo* expansion of stem and progenitor cells in co-culture of mobilized peripheral blood CD34<sup>+</sup> cells on human endothelium transfected with adenovectors expressing thrombopoietin, c-kit ligand, and Flt-3 ligand. *J Hematother Stem Cell Res* 2002;11:127-38

Flores-Guzman P, Gutierrez-Rodriguez M, Mayani H. *In vitro* proliferation, expansion, and differentiation of a CD34<sup>+</sup> cell-enriched hematopoietic cell population from human umbilical cord blood in response to recombinant cytokines. *Arch Med Res* 2002;33:107-14

Hashida R, Ogawa K, Miyagawa M, Sugita Y, Matsumoto K, Akasawa A, Saito H. Gene expression accompanied by differentiation of cord blood-derived CD34<sup>+</sup> cells to eosinophils. *Int Arch Allergy Immunol* 2001;125:2-6

Hebert MJ, Takano T, Holthofer H, Brady HR. Sequential morphologic events during apoptosis of human neutrophils. Modulation by lipoxygenase-derived eicosanoids. *J Immunol* 1996;157:3105-15

Heike T, Nakahata T. Stem Cell plasticity in the hematopoietic system. *Int J Hematol* 2004;79:7-14

Kim HL. Comparison of oligonucleotide-microassay and serial analysis of gene expression (SAGE) in transcript profiling analysis of megakaryocytes derived from CD34<sup>+</sup> cells. *Exp Mol Med* 2003;35:460-6

Lewis ID, Almeida-Porada G, Du J, Lemischka IR, Moore KA, Zanjani ED, Verfaillie CM. Umbilical cord blood cells capable of engrafting in primary, secondary, and tertiary xenogeneic hosts are preserved after *ex vivo* culture in a noncontact system. *Blood* 2001;97:3441-9

Petersson A, Richter J, Owman C. Flow cytometric mapping of the leukotriene B<sub>4</sub> receptor, BLT<sub>1</sub>, in human bone marrow and peripheral blood using specific monoclonal antibodies. *Int Immunopharmacol* 2003;3:1467-75

Piacibello W, Sanavio F, Garetto L, Severino A, Bergandi D, Ferrario J, Ragioli F, Berger M, Aglietta M. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. *Blood* 1997;89:2644-53

Rudolph IL, Kelley DS, Klasing KC, Erickson KL. Regulation of cellular differentiation and apoptosis by fatty acids and their metabolites. *Nutr Res* 2001;21:381-93

Shih CC, Hu MC, Hu J, Medeiros J, Forman SJ. Long-term *ex vivo* maintenance and expansion of transplantable human hematopoietic stem cells. *Blood* 1999;94:1623-36

Spanbroek R, Hildner M, Steinhilber D, Fusenig N, Yoneda K, Radmark O, Samuelsson B, Habenicht AJ. 5-lipoxygenase expression in dendritic cells generated from CD34<sup>+</sup> hematopoietic progenitors and in lymphoid organs. *Blood*. 2000; 96:3857-65

Terada Y, Hato F, Sakamoto C, Hasegawa T, Suzuki K, Nakamae H, Ohta K, Yamane T, Kitagawa S, Hino M. Thrombopoietin stimulates *ex vivo* expansion of mature neutrophils in the early stages of differentiation. *Ann Hematol* 2003;82:671-6

Toda A, Yokomizo T, Shimizu T. Leukotriene B<sub>4</sub> receptors. Prostaglandins Other Lipid Mediat 2002;68-69:575-85

Tong WG, Ding XZ, Hennig R, Witt RC, Standop J, Pour PM, Adrian TE. Leukotriene B<sub>4</sub> receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. *Clin Cancer Res* 2002;8:3232-42

Williams DA, Rios M, Stephens C, Patel VP. Fibronectin and VLA-4 in hematopoietic stem cell-microenvironment interactions. *Nature* 1991;352:438-41

Woo CH, Yoo HJ, Cho SH, Eom YW, Chun JS, Yoo YJ, Kim JH. Leukotriene B<sub>4</sub> stimulates Rac-ERK cascade to generate reactive oxygen species that mediates chemotaxis. *J Biol Chem* 2002;277:8572-8

Yokomizo T, Izumi T, Shimizu T. Leukotriene B<sub>4</sub>: metabolism and signal transduction. *Arch Biochem Biophys* 2001;385: 231-41

Yoo ES, Ryu KH, Park HY, Seong CM, Chung WS, Kim SC, Choi YM, Hahn MJ, Woo SY, Seoh JY. Myeloid differentiation of human cord blood CD34<sup>+</sup> cells during *ex vivo* expansion using thrombopoietin, flt3-ligand and/or granulocyte-colony stimulation factor. *Br J Haematol* 1999;105: 1034-40

Zhang X, Moilanen E, Adcock IM, Lindsay MA, Kankaanranta H. Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. *Life Sci* 2002;71:1523-34